These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 31694455)

  • 21. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
    Blum SM; Rouhani SJ; Sullivan RJ
    Immunol Rev; 2023 Sep; 318(1):167-178. PubMed ID: 37578634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
    Zhuang J; Du J; Guo X; Zhou J; Duan L; Qiu W; Si X; Zhang L; Li Y; Liu X; Wang H; Zhou D; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):799-804. PubMed ID: 32017466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.
    Chhabra N; Kennedy J
    J Med Toxicol; 2021 Oct; 17(4):411-424. PubMed ID: 33826117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients.
    Özdemir BC; Espinosa da Silva C; Arangalage D; Monney P; Guler SA; Huynh-Do U; Stirnimann G; Possamai L; Trepp R; Hoepner R; Salmen A; Gerard CL; Hruz P; Christ L; Rothschild SI
    Cancer Immunol Immunother; 2023 Jul; 72(7):1991-2001. PubMed ID: 37017694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
    Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of immune-related adverse events resulting from immune checkpoint blockade.
    Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system.
    Chen C; Zhang C; Jin Z; Wu B; Xu T
    Int J Clin Pharm; 2022 Jun; 44(3):689-697. PubMed ID: 35449347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.
    Balaji A; Zhang J; Wills B; Marrone KA; Elmariah H; Yarchoan M; Zimmerman JW; Hajjir K; Venkatraman D; Armstrong DK; Laheru DA; Mehra R; Ho WJ; Reuss JE; Heng J; Vellanki P; Donehower RC; Holdhoff M; Naidoo J
    J Oncol Pract; 2019 Sep; 15(9):e825-e834. PubMed ID: 31386608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
    Zhong H; Zhou J; Xu D; Zeng X
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
    Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
    JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
    Schulz TU; Zierold S; Sachse MM; Pesch G; Tomsitz D; Schilbach K; Kähler KC; French LE; Heinzerling L
    Eur J Cancer; 2022 Nov; 176():88-99. PubMed ID: 36198246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
    Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Immune Checkpoint Inhibitor-Induced Diabetes.
    Ruiz-Esteves KN; Shank KR; Deutsch AJ; Gunturi A; Chamorro-Pareja N; Colling CA; Zubiri L; Perlman K; Ouyang T; Villani AC; Florez JC; Gusev A; Reynolds KL; Miller KK; Udler MS; Sise ME; Rengarajan M
    JAMA Oncol; 2024 Oct; 10(10):1409-1416. PubMed ID: 39207773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Takada S; Hirokazu H; Yamagishi K; Hideki S; Masayuki E
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1697-1699. PubMed ID: 32592366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.
    Kawahira M; Kanmura S; Mizuno K; Machida K; Ohtsuka T; Sato M; Enokida H; Yamashita M; Kanekura T; Arima S; Nakamura N; Sugiura T; Yoshimoto K; Kobayashi H; Ishitsuka K; Suzuki S; Ueno S; Ido A
    PLoS One; 2022; 17(4):e0267572. PubMed ID: 35482642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma.
    Wang B; Hao X; Yan J; Li X; Zhao M; Han T
    J Transl Int Med; 2024 Jun; 12(3):225-243. PubMed ID: 39081283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
    Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
    Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.